UCB (OTCMKTS:UCBJF) Shares Gap Up – Should You Buy?

UCB SA (OTCMKTS:UCBJF)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $250.88, but opened at $258.4650. UCB shares last traded at $252.16, with a volume of 84 shares changing hands.

Analyst Ratings Changes

UCBJF has been the subject of a number of recent research reports. Jefferies Financial Group upgraded UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

UCB Stock Performance

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm’s 50 day moving average price is $277.48 and its 200-day moving average price is $292.61.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.